Novartis (NVS) to Release Quarterly Earnings on Thursday

Novartis (NYSE:NVS - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, July 17th. Analysts expect Novartis to post earnings of $2.37 per share and revenue of $13.94 billion for the quarter.

Novartis (NYSE:NVS - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.12 by $0.16. Novartis had a net margin of 24.70% and a return on equity of 39.44%. The company had revenue of $13.23 billion for the quarter, compared to the consensus estimate of $12.92 billion. During the same quarter in the previous year, the company earned $1.80 EPS. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Novartis Stock Up 1.0%

Shares of NYSE:NVS opened at $122.95 on Thursday. Novartis has a 52 week low of $96.06 and a 52 week high of $124.45. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.61 and a current ratio of 0.79. The company's fifty day moving average is $115.63 and its 200-day moving average is $109.42. The company has a market capitalization of $259.72 billion, a PE ratio of 19.21, a P/E/G ratio of 1.67 and a beta of 0.59.

Hedge Funds Weigh In On Novartis

Large investors have recently bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock worth $599,000 after purchasing an additional 2,666 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Novartis during the 1st quarter worth approximately $1,764,000. Finally, AQR Capital Management LLC raised its stake in shares of Novartis by 102.8% during the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company's stock worth $2,516,000 after purchasing an additional 11,444 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company's stock.

Analyst Upgrades and Downgrades

Separately, BNP Paribas raised Novartis to a "strong-buy" rating in a report on Tuesday, April 15th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $123.67.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.